EUCTR2006-005514-12-CZ进行中（未招募）不适用
A Phase II, Open-label Study of INNO-206 in Patients with Recurrent Extensive Small Cell Lung Cancer after First-line Platinum-based Therapy
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients must meet all of the following criteria for admission into the study:
- •(1) Informed consent must be obtained in writing for all patients prior to enrollment into the study.
- •(2) Be at least 18 years or older.
- •(3) Have a histologically or cytologically confirmed diagnosis of recurrent extensive small cell lung cancer (SCLC) at time of enrollment into the study.
- •(4) Have responded to first-line platinum-based chemotherapy, but progressed or relapsed greater than or equal to 60 days after completion of first-line therapy.
- •(5) Have measurable disease defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria.
- •(6) Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of less than or equal to 2.
- •(7) Have an estimated life expectancy of greater than or equal to 4 weeks.
- •(8) Be male or non-pregnant, non-lactating female patients. For US patients who are fertile, they must agree to use an effective barrier method of birth control (e.g., latex condom, diaphragm, or cervical cap) to avoid pregnancy while on therapy and for 90 days following the discontinuation of the study medication. For all non-US patients, who are fertile, they must agree to use two forms of barrier method contraception (e.g., latex condom AND a diaphragm or cervical cap) while on therapy and for 90 days following the discontinuation of the study medication
- •A non-fertile female is defined as:
- •-- Postmenopausal (amenorrheic for greater than or equal to 12 months)
- •-- Undergone a complete oopherectomy and hysterectomy
- •(9) Have a negative serum or urine pregnancy test within 7 days prior to the first dose of study medication (if patient is a female of childbearing potential).
- •(10) Have adequate organ function as indicated by the laboratory values (specified in the protocol) obtained within 14 days prior to the first dose of study drug.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients who meet any of the following criteria will be excluded from study admission:
- •(1) Are pregnant or lactating.
- •(2) Have received prior anthracycline therapy.
- •(3) Have participated in any investigational drug study within 30 days prior to study entry.
- •(4) Have received radiotherapy within 2 weeks (14 days) of treatment in this study.
- •(5) Have not recovered from acute toxicity of all previous therapy prior to enrollment.
- •(6) Have a history of a malignancy other than SCLC; exceptions to this include:
- •-- Curatively treated nonmelanomatous carcinoma of the skin or in situ carcinoma of the cervix; or prior low-grade, localized prostate cancer (Gleason score less than or equal to 6)
- •-- History of another malignancy that was curatively treated and no evidence of recurrence for a minimum of 5 years
- •(7) Have symptomatic central nervous system (CNS) metastases.
- •(8) Have any concurrent severe or uncontrolled medical disease (such as active systemic infection, hypertension, congestive heart failure = NYHA Grade II, myocardial infarction within 12 months before study start, severe rhythm disturbances, etc.) that, in the opinion of the Investigator, would compromise the safety of the patient or compromise the ability of the patient to complete the study.
- •(9) Have a psychiatric disorder(s) that would interfere with consent, study participation, or follow-up.
- •(10) Have received radiotherapy with >25% involvement of the bone marrow within 6 weeks prior to study start.
- •(11) Have a known hypersensitivity to doxorubicin, 5% D-(+)-sucrose, 10 mM sodium phosphate, and/or 0.3% N-acetyltryptophane
研究者
相似试验
进行中（未招募）
不适用
A Phase II, Open-label Study of INNO-206 in Patients with Recurrent Extensive Small Cell Lung Cancer after First-line Platinum-based TherapyRecurrent extensive small cell lung cancer after first-line platinum-based therapy.MedDRA version: 9.1Level: LLTClassification code 10041067Term: Small cell lung cancerEUCTR2006-005514-12-DEINNOVIVE Pharmaceuticals40
招募中
2 期
A Phase 2 clinical study to assess efficacy of Induction ipilimumab/nivolumab to spare the Bladder in urothelial bladder cancer (IndiBlade)Urothelial carcinoma of the bladder and bladder cancer10038364NL-OMON52087Antoni van Leeuwenhoek Ziekenhuis50
招募中
2 期
A phase 2 study to investigate the effectiveness of combination immunotherapy followed by chemoradiation of the tumor in patients with bladder cancer (Indi-blade).2024-512211-41-00Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting50
进行中（未招募）
1 期
A clinical trial with investigational compounds INC280 and BKM120 in adult patients with recurrent glioblastomaGlioblastomaEUCTR2013-000699-14-NLovartis Pharma Services AG100
进行中（未招募）
1 期
A clinical trial with investigational compounds INC280 and BKM120 in adult patients with recurrent glioblastoma.GlioblastomaEUCTR2013-000699-14-ESovartis Farmacéutica, S.A.66